Synovial sarcoma X breakpoint protein (SSX)

The Synovial sarcoma X breakpoint protein (SSX) family consists of several highly homologous proteins that function primarily as transcriptional repressors and are classified as cancer-testis antigens (CTAs). In healthy individuals, their expression is largely restricted to the testis, but they are aberrantly expressed in various malignancies, making them attractive targets for immunotherapy. The most prominent role of SSX is in synovial sarcoma, where a pathognomonic t(X;18) translocation fuses the SS18 gene with SSX1, SSX2, or SSX4, creating the oncogenic SS18-SSX fusion protein. This fusion protein disrupts the SWI/SNF (BAF) chromatin-remodeling complex by displacing the tumor suppressor SMARCB1, leading to widespread epigenetic dysregulation and driving tumor growth. Therapeutic strategies targeting SSX include TCR-engineered T-cell therapies and vaccines aimed at the CTA properties of the protein, as well as small molecules like HDAC and BRD9 inhibitors designed to degrade or inhibit the SS18-SSX fusion product. Additionally, metabolic vulnerabilities created by the presence of the fusion protein are being explored for targeted small-molecule intervention.

Other names

SSX familyCancer/testis antigen 5CT5Synovial sarcoma, X breakpointProtein SSX1Protein SSX2Protein SSX4

Immunotherapy targeting cancer-testis antigens; targeted degradation of the SS18-SSX fusion protein; disruption of the BAF (SWI/SNF) chromatin remodeling complex; inhibition of SUMOylation to reduce oncoprotein levels.